Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Trial Profile

Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs CD154 gene therapy (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2016 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2020.
    • 26 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Dec 2016.
    • 24 Mar 2016 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top